Clinical Trial

Racial Differences in Vasoconstriction

Study Description

The Effect of Endothelin and L-Arginine on Racial Differences in Vasoconstriction

The goal of the study is to examine the possible mechanisms of impaired cutaneous microvascular function through local heating along with administration of vasoconstrictors.

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Patients and healthy individuals accepted Patients and healthy individuals accepted

Drug - BQ-788

This intervention is aimed at blocking endothelin type B receptors to assess racial differences during vasoconstriction. The infusion rate will be 2 µl/min

Drug - BQ-123

This intervention is aimed at blocking endothelin type A receptors to assess racial differences during vasoconstriction. The infusion rate will be 2 µl/min

Drug - L-Arginine

A substrate that is administered to increase endogenous nitric oxide production. The infusion rate will be 2 µl/min

Drug - NG Nitro L Arginine Methyl Ester

L-Name is a NOS inhibitor that is administered to each site to allow for the quantification of NO contribution to vasodilation. The infusion rate will be 2 µl/min

Drug - Sodium Nitroprusside

SNP will be perfused through each site to induce maximal vasodilation. The infusion rate will be 2 µl/min

Drug - Lactated Ringer's

Lactated Ringer will serve as the control site. The infusion rate will be 2 µl/min

Additional Information

Official Study Title

The Effect of Endothelin and L-Arginine on Racial Differences in Vasoconstriction

Clinical Trial ID

NCT03679780

ParticipAid ID

erk2Ka